Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps
jRCT2031240234Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of lebrikizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change from baseline in participant-reported nasal congestion score severity at Week 24 and Change from baseline in endoscopic nasal polyp score at Week 24. Started Nov 2024; status: recruiting.
02
Drugs
lebrikizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on jRCT2031240234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240234.